Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Biotechnology
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29339
License Grant
Licensor hereby grants to Licensee, and Licensee accepts, subject to the terms and conditions of this Agreement, a royalty-bearing, worldwide, non-exclusive license during the term of this Agreement only, to use the know-how to research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Cells and Cell Lines.
License Property
Cells means the cells acceptably derived from the Cell Lines and additional cell lines derived from preimplantation embryos during the term of this Agreement, that are covered by (i.e., made or developed using) the know-how and/or are provided to Licensee by Licensor in accordance with the provisions of Articles 2 or 3, as applicable, of this Agreement. The Cell Lines will include, but not be limited to, those made animal product free and those with defined HLA types and determined to carry disease gene alleles.
Licensor is a leading fertility center that screens embryos for genetic disorders, such as cystic fibrosis and muscular dystrophy prior to implantation. The RGI hES lines include both normal cells and 88 cell lines identified as carrying a host of inherited genetic disease genes.
Field of Use
The rights granted apply to genetic disorders.
IPSCIO Record ID: 28404
License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, subject to the terms and conditions hereof a) A royalty bearing, exclusive license in the Territory in the Field and under the Licensed Technology to (a) research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, (b) research, develop, use, practice, sell, offer for sale, import and export Licensed Processes and (c) develop, use, perform, sell, offer for sale, import and export Licensed Services.
By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field for the following purposes to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays. b) A royalty bearing, twelve (12) month exclusive license in the Territory in the Field to expand in culture, prepare for sale, sell, offer for sale, import and export Act Animal Cell Lines. The twelve-month term of exclusivity granted to Licensee shall begin upon the date of the first sale of the Act Animal Cell Lines. Licensor and Licensee agree that after the twelve-month period of exclusivity has passed, Licensor and Licensee shall negotiate in good faith to establish reasonable minimum sales goals over reasonable evaluation periods in order to maintain Licensee’s exclusive rights hereunder. If Licensor fails to meet the minimum sales goals then Licensee’s exclusive rights shall revert to nonexclusive rights.
License Property
“Act Animal Cell Lines†shall mean cell lines of non-human animal origin developed by Act. These cell lines shall include but not be limited to murine and primate embryonic stem cells derived through parthenogenesis, nuclear transfer or otherwise isolated from fertilized blastocysts including the relevant information Licensor possesses associated with these cells, including but not limited to information on the cell’s karyotype, gene expression and growth characteristics.
PATENT RIGHTS
08/935,052 US 1997-09-22 CICM Cells and Non-Human Mammalian Embryos
6,235,970 2001-05-22 Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus
09/828,876 US 2001-04-10 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells UMASS
10/374,512 US 2003-02-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
60/161,987 US 1999-10-28 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
2,387,506 CA 2000-10-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
Declared patent interferences
a) Patent Interference No. 104,746, involving U.S. Patent No. 5,945,577 and U.S. Patent Application No. 09/650,194.
b) Patent Interference No. 105,192, involving U.S. Patent No. 6,235,970 and U.S. Patent Application No. 09/989,126.
Potential patent interferences, verbally threatened to be filed against the following patents
a) 6,215,041
b) 6,235,969
Field of Use
“Field†shall mean (1) the research, development, manufacture and selling of human and non-human animal cells and Act Animal Cell Lines for commercial research use, including small molecule and other drug testing and basic research, (2) the manufacture and selling of human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases, and (3) the use of Act Animal Cell Lines in the process of manufacturing and selling human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases but where the final marketed product does not include Act Animal Cell Lines (i.e. does not include the field of xenotransplantation); but Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.
IPSCIO Record ID: 28403
License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, subject to the terms and conditions hereof, a royalty bearing, exclusive license in the Territory in the Field and under the Licensed Technology to (a) research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, (b) research, develop, use, practice, sell, offer for sale, import and export Licensed Processes and (c) develop, use, perform, sell, offer for sale, import and export Licensed Services. By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays.
License Property
60/382,616 Nuclear Transfer-Generated Stem Cells for Transplantation Having Homozygous MHC Alleles, and Methods for Making and Using Such a Stem Cell Bank
09/736,268 Transfer to De-Differentiate Recipient Cells
Field of Use
Field shall mean (1) the research, development, manufacture and selling of human and non-human animal cells for commercial research use, including small molecule and other drug testing and basic research and (2) the manufacture and selling of human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases; but Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.
IPSCIO Record ID: 168
License Grant
Licensor hereby grants a royalty-bearing, worldwide, exclusive license, with the right to sublicense, to use the Patent Rights and Know-How to (a) research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Products, (b) research, develop, use, practice, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Processes, and (c) develop, use, perform, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Services.
Company granted an exclusive license to use its “ACTCellerate†embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
License Property
ACTCellerateâ„¢ is a recently discovered technology that allows the rapid isolation of novel highly purified embryonic progenitor cells. Embryonic progenitors are cells intermediate between embryonic stem cells and fully differentiated cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of embryonic stem cells. Using the ACTCellerate platform technology over 140 distinguishable novel progenitor cell lines have already been created, scaled-up, and banked. These unique cell lines may possess the ability to become a wide array of products never before available to the medical community, with potential applications in research, drug discovery, and human regenerative stem cell therapy.
The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use. Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.
The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.
Patent Rights
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06) Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006) Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.
IPSCIO Record ID: 383576
License Grant
Licensors, one being a University, grant a non-exclusive license under the Licensed Patents and Technology to make, have made, use, including use in the performance of services for, by or on behalf of its customers, have used, import, market and/or sell, in the Territory, Products designed and marketed solely for use in the Field of Use.
Licensee agrees to mark, and to require Affiliates to mark, Products with the appropriate patent notice as approved by Licensors, when appropriate.
License Property
The University Licensor and the Research Institute of the Hospital for Sick Children of Toronto, Ontario, Canada, have conducted research relating to cystic fibrosis.
Technology shall mean the information, manufacturing techniques, data, designs or concepts developed by Licensors, covering the gene for cystic fibrosis and uses thereof as covered by the claims of U.S. Patents entitled Cystic Fibrosis Gene.
Field of Use
The Field of Use shall refer to the field for which Product(s) may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Product(s) to be used for the research of, diagnosis of and screening for the disease cystic fibrosis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
